n3 PUFA and Muscle-disuse Atrophy in Young Women

NCT ID: NCT03059836

Last Updated: 2018-03-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-28
• Study Completion Date: 2018-02-28

Brief Summary

This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in women undergoing 2 weeks of unilateral limb immobilization. Assessments in skeletal muscle strength and skeletal muscle volume will also me made before, after and in recovery from immobilization.

Detailed Description

Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of reduced physical activity/muscle disuse that independently lower muscle mass and strength accelerating the aging process. The losses in muscle mass with aging and disuse are underpinned by feeding-induced declines in rates of muscle protein synthesis. Thus, strategies to enhance muscle protein synthesis could have clinical implications for those who wish to maintain metabolic health and function during times of muscle disuse.

Supplementation with n3 PUFA-enriched fish oil has been shown to potentiate rates of muscle protein synthesis in response to simulated feeding in both younger and older adults. Fish oil supplementation also has been efficacious in enhancing skeletal muscle strength during a period of resistance exercise training. However, no study has examined the impact of fish oil supplementation to enhance muscle protein synthesis and offset declines in muscle mass/strength during a period of immobilization.

Conditions

Muscle Atrophy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

n3 PUFA

Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)

Group Type: EXPERIMENTAL

n3 PUFA-enriched fish oil

Intervention Type: DIETARY_SUPPLEMENT

3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day

Placebo

Intervention: Organic Sunflower Oil 5000mg per day

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Organic Sunflower Oil 5000mg per day

Interventions

n3 PUFA-enriched fish oil

3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Organic Sunflower Oil 5000mg per day

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Female
• Aged 18-30 years

Exclusion Criteria

• Take any analgesic or anti-inflammatory drugs(s), prescription or non-prescription, chronically will be excluded
• A history of neuromuscular problems or muscle and/or bone wasting diseases
• Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin- or non-insulin dependent diabetes or other metabolic disorders-all ascertained through medical history screening questionnaires
• Use medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
• Fish allergy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Guelph

OTHER

Sponsor Role: collaborator

McMaster University

OTHER

Sponsor Role: lead

Responsible Party

Stuart Phillips

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stuart M Phillips, PhD

Role: PRINCIPAL_INVESTIGATOR

McMaster University

Locations

Exercise Metabolism Research Laboratory, McMaster Univeristy

Hamilton, Ontario, Canada

Countries

Canada

Other Identifiers

1457

Identifier Type: -

Identifier Source: org_study_id